D. Voliotis

22.4k citations
48 papers · 3.0k indexed · 2 hit papers · h-index 20

D. Voliotis

47 papers receiving 2.9k citations

Hit Papers

Efficacy and safety of sorafenib in patients with advan...6562004202620112018200400600

Peers

D. Voliotis
Comparison fields: 5 of 86
  • Hepatology 1.4k
  • Pathology and Forensic Medicine 666
  • Oncology 953
  • Cancer Research 451
  • Hematology 312
Replace John Kauh with:
John Kauh United States
Gerold Meinhardt United States
재연 정
Heinz‐Josef Klümpen Netherlands
O. Kisker Germany
Heike Richly Germany
Éveline Boucher France
Mohamed Bouattour France
Tsai‐Shen Yang Taiwan
Scot Ebbinghaus United States
D. Voliotis relative to John Kauh United States John Kauh's profile →
Citations per field
00.5×1.5×2.5×
John Kauh · 1×
Citations per year

Countries citing papers authored by D. Voliotis

Since Specialization
Citations

This map shows the geographic impact of D. Voliotis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Voliotis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Voliotis more than expected).

Fields of papers citing papers by D. Voliotis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Voliotis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Voliotis. The network helps show where D. Voliotis may publish in the future.

Co-authorship network

The 25 scholars most cited alongside D. Voliotis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Voliotis Line = papers co-authored together D. Voliotis links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20213
2 2012102
3
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialbreakdown →
2012656
4 2012222
5 200810
6 200845
7 2007163
8 2006115
9 200687
10 200538
11 2005322
12 200421
13 200319
14 200321
15 200216
16 200292
17 19986
18 19948
19 199411
20 199410

About D. Voliotis

D. Voliotis is a scholar working on Hepatology, Cancer Research, Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 48 papers that have together received 3.0k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Cancer, Lipids, and Metabolism (8 papers), Colorectal Cancer Treatments and Studies (8 papers), Liver Disease Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer Mechanisms and Therapy (6 papers), Melanoma and MAPK Pathways (6 papers) and Hepatitis B Virus Studies (5 papers). The work is most often cited by research in Hepatology (1.4k citations), Pathology and Forensic Medicine (666 citations), Oncology (953 citations), Cancer Research (451 citations) and Hematology (312 citations). D. Voliotis has collaborated with scholars based in Germany, United States and France. Frequent co-authors include M. Moscovici, Dirk Strumberg, Josep M. Llovet, Jordi Bruix, Jean‐Luc Raoul, M. E. Scheulen, Vincenzo Mazzaferro, S. Seeber, Heike Richly and Brian Schwartz. Their work appears in journals such as Journal of Clinical Oncology, Journal of Hepatology, Annals of Oncology, European Journal of Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026